Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. - Wikidata - wikimedia - TriplyDB

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

http://www.wikidata.org/entity/Q40281409

about

PSA and beyond: alternative prostate cancer biomarkers Virus encoded circulatory miRNAs for early detection of prostate cancer Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer.Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.Translational and clinical implications of the genetic landscape of prostate cancer.Novel biomarkers for the detection of prostate cancer.Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference?Recent progress and perspectives on prostate cancer biomarkers.ERG expression in prostate cancer: biological relevance and clinical implication.The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study.PBX3 is a putative biomarker of aggressive prostate cancer.Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.What's new in screening in 2015?Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.Current Management Strategy for Active Surveillance in Prostate Cancer.The potential use of urine cell free DNA as a marker for cancer.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.The role of prostate cancer biomarkers in undiagnosed men.miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.The context of prostate cancer genomics in personalized medicine.Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.Novel insights into chromosomal conformations in cancer.From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer.Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.The molecular biology of prostate cancer: current understanding and clinical implications.Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.Prostate cancer screening in Europe and Asia.The crucial role of multiomic approach in cancer research and clinically relevant outcomes.Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.

P2860

Q26770646-1E1F09EF-FDB1-4421-BC70-6F2308181FEA Q26776424-9F0C0B1A-A99D-4DD9-A7CD-7D6074768205 Q27323950-D006086C-3943-4395-B4E4-A16A202AF04E Q28075610-090D2A8B-7774-46B9-94E3-6544AB994759 Q30395328-C41BAB50-4C06-4940-A6D1-C76BFC793BB4 Q33890201-31E8681F-B671-4578-890E-263C43796D97 Q36157852-3C179A27-67FF-4A16-952A-D3B6F29CD295 Q36336025-35D53FD4-CEE0-48A0-9E8B-97336C866C4D Q37270512-85D6E303-93E2-4062-AC85-80126B0BAA15 Q37708174-827D2622-597B-43FD-8B83-82B969765494 Q37724539-A7C7A893-F756-43FE-89E7-44E9841A5306 Q37736079-8CC982E5-8D1E-4952-8765-98CC0F02945C Q38681610-E06D189F-E43F-4F07-A2AB-8472853EB4ED Q38684598-E614C12F-C441-4344-8B2C-1B18BC9FABF5 Q38765965-75C65708-D768-4001-9297-D46C96C30A04 Q38786630-9CAA6AF2-E87F-4C63-B62D-B53C817B4859 Q38871819-05976AAD-84AC-4A20-A614-EB376F6497D9 Q38874800-DADF4D17-706B-4D0D-A2BF-448935234DFE Q38950445-0FFE260E-BE69-42AF-84CF-CC6218F062D4 Q38950908-E0CA2BD2-A688-45C5-BB55-6523242197C5 Q38994581-19DF8DC6-AA87-49A0-898C-DAFC93C91E28 Q39108592-15263AF7-B28E-48BF-8CED-36F900A7CDDA Q39140686-C9F42D5F-BB6C-4635-8AF3-7513C1848983 Q39214638-B94B1869-2282-4E94-9880-B7573DC3A979 Q40461863-BD46FF95-A18A-4AA0-BE4F-23DA4171A0DF Q40461954-92561F1F-D4EC-46AB-9363-4D2938A380CF Q41212675-A3BEE71E-428B-4C18-BA12-C4D1FE0A0A42 Q41839243-E8C89DE4-266A-42D7-BBB5-87231D0BB20A Q42335698-DC690887-22A8-408E-A31C-7807817FE213 Q42345804-B66E91BF-5915-4F28-9122-411CC6489679 Q44871406-0CA5C4B8-B85F-4373-A7D0-7A4CB20F5471 Q47098649-3E8DAF2D-4B85-4D44-9491-87B21290262E Q47287055-CAB07707-3CD5-4E6D-8174-911A843C22A8 Q47436741-AB5B4FF2-8343-4E66-B688-730AB535C646 Q48252578-98DEEA71-98DA-404A-80C5-61C874991E34 Q49546811-D2C077CF-CB3B-46BD-B3BE-F231D28E4E02 Q50107743-BBD72F57-3C71-49BF-8998-8448E2AA99F2 Q51771288-3FB32781-3D8F-4C9D-A2A5-6702BABA881C Q52363678-4A053A07-36AB-40B6-8A72-ECCE2EFB30C3 Q52569296-4E9C18DB-8145-4E00-8F7F-0198F521B2EC

P2860

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

http://www.wikidata.org/entity/Q40281409

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

@en

type

label

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

@en

prefLabel

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

@en

P1433

Q40281409-DD0D8F23-B0B4-417B-9BBC-306C03AD6F36

P1476

Q40281409-56591224-D11E-4AA4-B807-42149C28197B

P2093

Q40281409-1AEA8FA0-DD1D-4891-A995-CDBCA9C00D84

Q40281409-1DFBE424-3AA4-424C-8ACE-BB85E76C51A1

Q40281409-1EC7AB6D-2C07-44F3-AD99-35B3DE3F9771

Q40281409-43F2A6DD-D619-4FDA-93E8-C1D0EFF36C31

Q40281409-621ABCE3-63E7-4D60-893D-0B53FB48552B

Q40281409-6C931640-5984-4722-B0FA-84B74D1814FA

Q40281409-77204780-E91A-4467-8C40-6E182DF76AFA

Q40281409-7D81C26C-7B25-4890-9246-D9C1B95063B8

Q40281409-AC0A09E7-45E8-4047-9416-FE72E8A6807B

Q40281409-D296EFA5-A40F-42AC-85D8-E8C029D86FD6

P2860

Q40281409-0282DFE5-219F-41A7-A973-0821984D7C65

Q40281409-04D0F2D4-D343-467F-8B33-ACE31237DAC9

Q40281409-11F67977-D7A6-4901-88B2-BF3E3B985D0A

Q40281409-27CA1913-463E-4CF9-99C1-980F80DF888D

Q40281409-30E22492-5C5B-4621-9864-9C9E625A914F

Q40281409-39E01964-92D0-4E2A-A6B6-D2987B532052

Q40281409-4ABD0F11-2395-48C0-BD3F-5A612F85AC95

Q40281409-50B7AA66-08D7-4791-8BE7-95B7C3D33913

Q40281409-542B0158-E279-4D93-BF77-080CFE689845

Q40281409-614812FE-8B8E-45D1-8C23-968E29A4D8FE

P304

Q40281409-0BCC4E84-95CC-45F3-9B4F-AA9E5FE7C11C

P31

Q40281409-12E35A6B-13F7-415A-AFEE-D8544F63DF29

P356

Q40281409-83196487-03A0-43FE-9CF8-D1B2C1D6F639

P407

Q40281409-04A8B87C-81D8-4DBE-B529-E4C06DCADC3C

P433

Q40281409-D7C758D1-28E8-4F67-AF1E-39ED550A6AE3

P478

Q40281409-47BF74A0-E839-4771-A898-9A4CEB150D1E

P50

Q40281409-DEBD97B9-1373-43F6-9708-1A5FC0869743

P577

Q40281409-279766F3-0ADD-4577-86A4-F43DB8ACA510

P698

Q40281409-08816775-546A-4118-BC7B-B404BE30E9B9

P932

Q40281409-FB9F32D5-F039-401C-BA28-3EDD782D6518

P356

J.EURURO.2015.04.039

P1433

European Urology

P1476

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

@en

P2093

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Jack Groskopf

http://www.w3.org/2001/XMLSchema#string

Javed Siddiqui

http://www.w3.org/2001/XMLSchema#string

John R Day

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

L Priya Kunju

http://www.w3.org/2001/XMLSchema#string

Petrea Hodge

http://www.w3.org/2001/XMLSchema#string

Robert J Lonigro

http://www.w3.org/2001/XMLSchema#string

Rodney L Dunn

http://www.w3.org/2001/XMLSchema#string

Sarah Meyer

http://www.w3.org/2001/XMLSchema#string

P2860

Emerging PSA-based tests to improve screening

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Critical review of prostate cancer predictive tools

Decision curve analysis: a novel method for evaluating prediction models

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

What do the screening trials really tell us and where do we go from here?

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2015.04.039

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Daniel H Hovelson

P577

2015-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25985884

http://www.w3.org/2001/XMLSchema#string

P932

4644724

http://www.w3.org/2001/XMLSchema#string